Skip to main content
. 2023 Jan 11;10:100139. doi: 10.1016/j.lansea.2022.100139

Table 1.

Treatment allocation.

Phase Cohorts Investigational products Number of Participants
Phase 2 (n = 200) Safety Cohort (n = 200) SII-NVX-CoV2373 150
Placebo 50
Phase 3 (n = 1400) Safety Cohort (n = 940) SII-NVX-CoV2373 705
Control vaccine (NVX-CoV2373) 235
Immunogenicity and Reactogenicity Cohort (n = 460) SII-NVX-CoV2373 345
Control vaccine (NVX-CoV2373) 115